nonacog gamma: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in haemophilia care.
• Individual response varies; assess clinical haemostasis and plasma factor IX activity, particularly around major surgery.
• Record product name and batch number to maintain biological-product traceability.
• Initial exposure requires particular vigilance for hypersensitivity and inhibitors, especially with high-risk F9 variants.

Contraindications and cautions

• Hypersensitivity to nonacog gamma or any excipient
• Known allergy to hamster protein
• Use caution where thrombosis or disseminated intravascular coagulation risk is increased, including liver disease, postoperative states and newborn infants.
• Consider cardiovascular risk and complications associated with central venous access devices.

Monitoring

• Clinical bleeding control
• Plasma factor IX activity using an appropriate assay
• Neutralising factor IX inhibitors when response is inadequate or allergic reactions occur
• Signs of hypersensitivity during infusion
• Clinical and laboratory signs of thrombosis or consumptive coagulopathy in at-risk patients

Clinical pharmacology

Nonacog gamma is a recombinant, vitamin K-dependent factor IX glycoprotein produced in a Chinese hamster ovary cell line. Replacement increases plasma factor IX activity and temporarily corrects the deficient coagulation pathway.

Formulation and product differences

• The selected presentations are powder-and-solvent kits for intravenous injection and include a needle-free reconstitution device.
• The presentations differ in factor IX content and concentration after reconstitution but use the same supplied solvent volume.
• The preparation must not be mixed with other medicines; plastic luer-lock syringes are required.

Injection

Route: Parenteral

Strengths: 1000 units, 2000 units